EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy

Aldostefano Porcari iD, Yousuf Razvi iD, Ambra Masi iD, Rishi Patel, Adam Ioannou, Muhammad U Rauf, David F Hutt, Dorota Rowczenio, Janet Gilbertson, Ana Martinez-Naharro, Lucia Venneri, Carol Whelan und 8 weitere

European Journal of Heart Failure · 01.04.2023 · 25 (4) · 515-524

DOI: 10.1002/ejhf.2776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 30.01.2023. Verfasst von Aldostefano Porcari und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, London, UK. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Heart Failure, Cardiomyopathies. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin amyloid cardiomyopathy (ATTR-CM) is often assumed to be associated with wild-type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing. We sought to estimate the prevalence, clinical characteristics and prognostic implications of transthyretin (TTR) variants among elderly patients diagnosed with ATTR-CM. Methods and results Data from consecutive patients over 70 years of age diagnosed with ATTR-CM at the UK National Amyloidosis Centre between January 2010 and August 2022 were retrospectively evaluated. All patients underwent clinical evaluation, biochemical tests, echocardiography and TTR genotyping. The study outcome was all-cause mortality. The study population consisted of 2029 patients with ATTR-CM (median age 79 years at diagnosis, 13.5% females, 80.4% Caucasian). Variant ATTR-CM (ATTRv-CM) was diagnosed in 20.7% (n = 421) of the study population of whom 327 (77.7%) carried V122I, 47 (11.2%) T60A, 16 (3.8%) V30M and 31 (7.3%) other pathogenic TTR variants. During a median (range) follow-up of 29 (12–48) months, ATTRv-CM was associated with increased all-cause mortality compared to ATTRwt-CM, with the poorest survival observed in V122I-associated ATTRv-CM (p < 0.001). Univariable and multivariable logistic regression analyses in those with ATTR-CM showed younger age at diagnosis (odds ratio [OR] 0.85 per year, p < 0.001), female sex (OR 2.73, p < 0.001), Afro-Caribbean ethnicity (OR 65.5, p < 0.001), atrial fibrillation (OR 0.65, p = 0.015), ischaemic heart disease (OR 0.54, p = 0.007), peripheral polyneuropathy (OR 5.70, p < 0.001) and orthostatic hypotension (OR 6.29, p < 0.001) to be independently associated with ATTRv-CM.

Conclusion

Up to 20.7% of elderly patients with ATTR-CM have a pathogenic TTR variant. These findings support routine sequencing of the TTR gene in all patients with ATTR-CM regardless of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialHeart FailureCardiomyopathiesAgedHumansFemaleAged, 80 and overMalePrevalencePrealbuminRetrospective Studies

Stichwörter der Autor:innen

Amyloid cardiomyopathyElderlyEpidemiologyHereditary transthyretin amyloidosisTransthyretin genetic testing

Substanzen

Prealbumin

Autor:innen und Institutionen

  • National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
  • Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.
  • European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart).

ORCID-Profile: Aldostefano Porcari, Yousuf Razvi, Ambra Masi, Gianfranco Sinagra, Marianna Fontana

Förderung

  • British Heart Foundation

Zitieren

APA

Porcari, A., Razvi, Y., Masi, A., Patel, R., Ioannou, A., Rauf, M. U., Hutt, D. F., Rowczenio, D., Gilbertson, J., Martinez-Naharro, A., Venneri, L., Whelan, C., Lachmann, H., Wechalekar, A., Quarta, C. C., Merlo, M., Sinagra, G., Hawkins, P. N., Fontana, M., & Gillmore, J. D. (2023). Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure, 25(4), 515-524. https://doi.org/10.1002/ejhf.2776

Vancouver

Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. 2023;25(4):515-524. doi:10.1002/ejhf.2776

BibTeX
@article{Porcari2023,
  author = {Porcari, Aldostefano and Razvi, Yousuf and Masi, Ambra and Patel, Rishi and Ioannou, Adam and Rauf, Muhammad U and Hutt, David F and Rowczenio, Dorota and Gilbertson, Janet and Martinez-Naharro, Ana and Venneri, Lucia and Whelan, Carol and Lachmann, Helen and Wechalekar, Ashutosh and Quarta, Candida Cristina and Merlo, Marco and Sinagra, Gianfranco and Hawkins, Philip N and Fontana, Marianna and Gillmore, Julian D},
  title = {Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy},
  journal = {European Journal of Heart Failure},
  year = {2023},
  volume = {25},
  number = {4},
  pages = {515--524},
  doi = {10.1002/ejhf.2776}
}
Kostenlos starten →